http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101397295-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc5bf6d1281c52501b840b0e3530fd78
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
filingDate 2008-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2012-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99b9fd20d10e915315e6bbb61727d1b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a8e1cdac63d8bfa0e61c655f28eb7a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_313150aa9ce1066a6c1bd210c5b2dfc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f68518f56493fb5f17f18a4fdbf43ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df5816d0c38bdec599c63a727f7fa6b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5c5a4ba9b43144d5a0691140863e4df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9aed365bce0e7e224d82de57e0641586
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_106e1003fd1002881489a820fc90f3f1
publicationDate 2012-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-101397295-B
titleOfInvention 2-dihydroindolemanone derivates as histone deacetylase inhibitor, preparation method and use thereof
abstract The invention discloses 2-isatin derivatives, the preparation method and the application. The structure of the invention is shown as the formula (I), wherein, the definitions of R<1>, R<2>, R<3>, R<4>, R<5>, X, Ar and n are shown in the description of instruction. The compound is provided with the restraining activity against histone deacetylase so as to treat the diseases relevant to the abnormal condition of the histone deacetylase, including Rubinstein-Taybi II-syndrome, fragile x syndrome, leukemia, cancer, immunological diseases, cardiac hypertrophy, bone diseases, nervous system diseases and neurodegenerative diseases.
priorityDate 2008-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007061880-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID158580160
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163463357
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467778838
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID157722559
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465017340
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467114703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448336535
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449486190
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467602307

Total number of triples: 34.